Research

Pioneering clinical studies that transform scientific breakthroughs into patient outcomes.

In 2024 alone, we invested €287 million in research and development, conducted 34 clinical trials across 19 countries, and published 156 peer-reviewed papers. Our Phase III pipeline currently includes 7 promising compounds targeting autoimmune disorders and metabolic diseases.